O5 Fixed ‘low dose’ irinotecan and raltirexed provide TTP comparable to other regimens, in oxaliplatin refractory colorectal cancer patients. The importance of disease stabilisation without administering MTD to older patients

Successful and Well-Tolerated Second Line Therapy with Cetuximab, Irinotecan, and Raltitrexed in Progressive Liver Disease Due to Metastatic Colon Cancer

“…Raltitrexed has an important renal clearance and can be therefore safely administered in patient with liver insufficiency [12]. In this case, we chose the fixed dose combination of raltitrexed 2.6 and 350 mg of irinotecan, which we showed to be effective and safe in a second-line setting in elderly patients after oxaliplatin failure [13].…”